Ever since monetizing its stake in multiple sclerosis drug Tysabri, Elan Pharmaceuticals has been at the center of attention. It is seemingly reinventing its business on the fly by making a flurry of deals in the past few days while at the same time being doggedly pursued by Royalty Pharma.

In this video, health-care analyst David Williamson discusses Elan's recent wheeling and dealing and whether it is in the best interests of investors.